Abiraterone Acetate + Tildrakizumab
Phase 1/2Terminated 1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration Resistant Prostate Cancer
Conditions
Metastatic Castration Resistant Prostate Cancer
Trial Timeline
Dec 1, 2020 → Nov 15, 2023
NCT ID
NCT04458311About Abiraterone Acetate + Tildrakizumab
Abiraterone Acetate + Tildrakizumab is a phase 1/2 stage product being developed by Sun Pharmaceutical for Metastatic Castration Resistant Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04458311. Target conditions include Metastatic Castration Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration Resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04458311 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Metastatic Castration Resistant Prostate Cancer